INDICATION AND IMPORTANT SAFETY INFORMATION
TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.  ...More

An app designed to help those living with Cystic Fibrosis manage their daily regimen

App Store

Google Play

Treatment Reminders

  • Patients can set up treatment reminders for medications and activities to focus on accurate to focus on adherence with CF treatment regimens
  • Allows for full customization based on dosing frequency so that the app can deliver accurate reminders throughout the user’s day, week, month

TOBI Podhaler Resources

PodManagerTM app provides a library of educational content focused on towards the proper use of TOBI Podhaler.

View step-by-step video instructions on administration

  • How to prepare the first dose
  • Loading the capsule
  • Complete dosing and aftercare

Information for TOBI Podhaler patient support programs such as PodCare+ and Savings Card signup

Adherence Tracking and Analytics

  • Treatment tracking function allows the user to record each time they have taken a dose, completed a treatment, or finished an activity.
  • Adherence data compiled and displayed in graphs, calendar, and reports allows users to see proficiency with their overall CF treatment regimen.
  • Export data to PDF or share progress via social media.

Air Quality

Real-time air quality alerts deliver a convenient update about the current outside environment based on the user’s location

Air Quality Index measurements are based on hourly readings for your location.

Air Quality Index (AQI)

  • 0-50 implies that air quality is considered as good and pollution poses little or no risk
  • 51-100 implies that air quality is acceptable but poses a moderate health concern for people with respiratory disease.
  • 101-150 Members of sensitive groups may experience health effects. The general public is less likely to be affected.
  • 151-200 indicates that air quality is unhealthy and members of sensitive groups may experience more serious health effects
  • 201-300 & above indicates that it is very unhealthy and hazardous for everyone.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.